PAS
AQST icon

PKS Advisory Services’s Aquestive Therapeutics AQST Stock Holding History

PKS Advisory Services’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.9K Hold
12,000
– – 0.01% 374
2026
Q1 		$49.8K Buy
+12,000
New +$48.7K 0.01% 227
2025
Q3 		– Sell
-17,650
Closed -$58.4K – 247
2025
Q2 		$58.4K Hold
17,650
– – 0.01% 257
2025
Q1 		$51.2K Hold
17,650
– – 0.01% 239
2024
Q4 		$62.8K Buy
+17,650
New +$81.4K 0.02% 242

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

PKS Advisory Services's AQST Position: Q2 2026 in Review

PKS Advisory Services held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 12,000 shares worth $49.9K. The position accounts for 0.01% of the portfolio, ranked #374.

PKS Advisory Services first reported a position in AQST in Q4 2024 and has held it in 5 quarters since. The position peaked at $62.8K in Q4 2024. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • PKS Advisory Services held 12,000 shares of Aquestive Therapeutics worth $49.9K as of Q2 2026.
  • PKS Advisory Services left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up 0.01% of PKS Advisory Services's portfolio in Q2 2026, its #374 holding.
  • PKS Advisory Services first reported a position in Aquestive Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • PKS Advisory Services's Aquestive Therapeutics position peaked at $62.8K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on PKS Advisory Services's 13F filing for Q2 2026, filed 4 Aug 2026.